Earnings Call Scheduled for 8:30 p.m. ET on November 18, 2024
MILPITAS, Calif., Nov. 5, 2024 /PRNewswire/ — Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its third quarter 2024 unaudited financial results after the market close on Monday, November 18, 2024.
Management will hold a conference call at 8:30 p.m. Eastern Time on Monday, November 18, 2024. Listeners may access the call by dialing:
US (Toll Free): |
+1-888-346-8982 |
|
International: |
+1-412-902-4272 |
|
Mainland China (Toll Free): |
400-120-1203 |
|
Hong Kong (Toll Free): |
800-905-945 |
|
Hong Kong: |
+852-3018-4992 |
Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for “Zepp Health Corporation.”
Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.
A telephone replay will be available one hour after the end of the conference until November 25, 2024 by dialing the following telephone numbers:
US (Toll Free): |
+1-877-344-7529 |
International: |
+1-412-317-0088 |
Replay Passcode: |
5720021 |
About Zepp Health Corporation
Zepp Health (NYSE: ZEPP), a global smart wearable and health technology leader, empowers users to live their healthiest lives through its leading consumer brands, including Amazfit, Zepp Clarity, and Zepp Aura. Leveraging its proprietary Zepp Digital Health Management Platform, Zepp Health delivers actionable insights and guidance to users worldwide. With a presence in over 90 countries and a robust ecosystem of products and services, Zepp Health is at the forefront of advancing wearable intelligence and digital health technology.
For more information on Zepp Health and its products, please visit www.zepp.com.
For investor and media inquiries, please contact:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com
Piacente Financial Communications
Email: zepp@tpg-ir.com
SOURCE Zepp Health Corp.
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…